Yale Interventional Immunology Center
6 Devine Street
Fl 2nd Ste Suite 2B
North Haven, CT 06473
- Yale Interventional Immunology Center6 Devine StreetFl 2nd Ste Suite 2BNorth Haven, CT 06473
Christina Price, MD
Allergy & Clinical Immunology, Pediatric Allergy & Immunology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Allergy & Immunology
Titles
- Associate Professor of Medicine (Allergy & Immunology)
- Clinical Chief of Allergy and Immunology, Rheumatology, Allergy, & Immunology
- VA Medical Center Section Chief, Allergy and Clinical Immunology
Education & Training
- FellowYale University (2012)
- Chief ResidentYale University Bridgeport Hospital (2009)
- ResidencyYale University Bridgeport Hospital (2008)
- Post Doctoral FellowshipJohns Hopkins University (2006)
- InternshipBoston Medical Center- Boston University (2004)
- MDSaint Louis University School of Medicine (2003)
- BASaint Louis University, Economics, Biology (1999)
Additional Information
Honors & Recognitions
- Advanced Emerging Leaders Program: Yale Medicine (2018)
- Emerging Leaders Program: Yale Medicine (2017)
- Elected Early Career Member of the Immunology Community of Practice (COP) Leadership Committee: FOCIS (Federation of Clinical Immunology Societies) (2013)
- Advanced Course in Basic and Clinical Immunology Travel Award: FOCIS (Federation of Clinical Immunology Societies) (2012)
- All-USA Academic Second Team: USA Today (1995)
- Presidential Scholar: Saint Louis University (1995), (1996), (1997), (1998)
- Medical Scholar: Saint Louis University (1995)
Professional Service
- Plasma Protein Therapeutics Association (PPTA) (2021 - Present): featured speaker in a Roundtable on Ig use in the United states
- Chest (2020 - Present): Reviewer
- Ad hoc COVID-19 Treatment group (2020 - Present): Reviewed literature and advised on treatment protocols during the COVID-19 pandemic
- Geriatric Chief Search Committee (2019 - 2021): Committee Member
- Yale New Haven Hospital (2019 - Present): Physician Steward for IVIG usage at Yale New Haven Hospital
- Yale (2018 - 2019): Allergy Immunology faculty recruitment search committee
- Yale Medicine (2018): Patient Access Advisory Committee: Change Management and Communication Yale Medicine
- Yale Internal Medicine (2018 - Present): representing Allergy and Immunology in Internal Medicine Clinical Leadership Meetings
- Oncology (2018 - Present): Reviewer
- Grifols (2015 - Present): Advisory Board member to Grifols regarding IgG replacement therapy use, major obstacles in the field, research initiatives and future directions
Publications
- Wang SY, Juthani PV, Borges KA, Shallow MK, Gupta A, Price C, Won CH, Chun HJ. Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era. The Lancet. Microbe 2022, 3: e4-e5. PMID: 34901896, PMCID: PMC8641954, DOI: 10.1016/S2666-5247(21)00306-2.
- Krantz MS, Kwah JH, Stone CA, Phillips EJ, Ortega G, Banerji A, Blumenthal KG. Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. JAMA Internal Medicine 2021, 181: 1530-1533. PMID: 34309623, PMCID: PMC8314170, DOI: 10.1001/jamainternmed.2021.3779.
- WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group., Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty JS, Berry LR, Broman N, Cavalcanti AB, Colman R, De Buyser SL, Derde LPG, Domingo P, Omar SF, Fernandez-Cruz A, Feuth T, Garcia F, Garcia-Vicuna R, Gonzalez-Alvaro I, Gordon AC, Haynes R, Hermine O, Horby PW, Horick NK, Kumar K, Lambrecht BN, Landray MJ, Leal L, Lederer DJ, Lorenzi E, Mariette X, Merchante N, Misnan NA, Mohan SV, Nivens MC, Oksi J, Perez-Molina JA, Pizov R, Porcher R, Postma S, Rajasuriar R, Ramanan AV, Ravaud P, Reid PD, Rutgers A, Sancho-Lopez A, Seto TB, Sivapalasingam S, Soin AS, Staplin N, Stone JH, Strohbehn GW, Sunden-Cullberg J, Torre-Cisneros J, Tsai LW, van Hoogstraten H, van Meerten T, Veiga VC, Westerweel PE, Murthy S, Diaz JV, Marshall JC, Sterne JAC. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA 2021.
- Azmy V, Kaman K, Tang D, Zhao H, Dela Cruz C, Topal JE, Malinis M, Price CC. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19. Journal Of Clinical Immunology 2021, 41: 738-747. PMID: 33459964, PMCID: PMC7812117, DOI: 10.1007/s10875-020-00949-6.
- Kaman K, Azmy V, Chichra A, Britto-Leon C, Price C. Cytokine profiles in severe SARS-CoV-2 infection requiring extracorporeal membrane oxygenation support. Respiratory Medicine Case Reports 2021, 33: 101376. PMID: 33680800, PMCID: PMC7925237, DOI: 10.1016/j.rmcr.2021.101376.
- Zhou Z, Price CC. Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease. Expert Opinion On Investigational Drugs 2020, 29: 1407-1412. PMID: 33094669, DOI: 10.1080/13543784.2020.1840549.
- Sheehan K, Price C, Hafez N. Optimizing Care for Patients With Adverse Events From Immunotherapeutics. Cancer Journal (Sudbury, Mass.) 2020, 26: 537-542. PMID: 33298725, DOI: 10.1097/PPO.0000000000000492.
- Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes. Chest 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.
- Subtle But Clinically Significant: A Review of Antibody Deficiency in AdultsHarada K, Price C. Subtle But Clinically Significant: A Review of Antibody Deficiency in Adults, Clin Pulm Med. 26(3):71-75 May 2019
- Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, Hoshino A, Kobayashi M, Imai K, Takagi M, Dybedal I, Haddock JA, Sansom DM, Lucena JM, Seidl M, Schmitt-Graeff A, Reiser V, Emmerich F, Frede N, Bulashevska A, Salzer U, Schubert D, Hayakawa S, Okada S, Kanariou M, Kucuk ZY, Chapdelaine H, Petruzelkova L, Sumnik Z, Sediva A, Slatter M, Arkwright PD, Cant A, Lorenz HM, Giese T, Lougaris V, Plebani A, Price C, Sullivan KE, Moutschen M, Litzman J, Freiberger T, van de Veerdonk FL, Recher M, Albert MH, Hauck F, Seneviratne S, Pachlopnik Schmid J, Kolios A, Unglik G, Klemann C, Speckmann C, Ehl S, Leichtner A, Blumberg R, Franke A, Snapper S, Zeissig S, Cunningham-Rundles C, Giulino-Roth L, Elemento O, Dückers G, Niehues T, Fronkova E, Kanderová V, Platt CD, Chou J, Chatila TA, Geha R, McDermott E, Bunn S, Kurzai M, Schulz A, Alsina L, Casals F, Deyà-Martinez A, Hambleton S, Kanegane H, Taskén K, Neth O, Grimbacher B. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. The Journal Of Allergy And Clinical Immunology 2018, 142: 1932-1946. PMID: 29729943, PMCID: PMC6215742, DOI: 10.1016/j.jaci.2018.02.055.
- Barmettler S, Price C. Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab--for how long? The Journal Of Allergy And Clinical Immunology 2015, 136: 1407-9. PMID: 26277594, DOI: 10.1016/j.jaci.2015.06.035.
Departments and Programs
- Allergy & Clinical Immunology
- Internal Medicine
Locations
Yale Interventional Immunology Center
6 Devine Street
Fl 2nd Ste Suite 2B
North Haven, CT 06473
- Yale Interventional Immunology Center6 Devine StreetFl 2nd Ste Suite 2BNorth Haven, CT 06473
Titles
- Associate Professor of Medicine (Allergy & Immunology)
- Clinical Chief of Allergy and Immunology, Rheumatology, Allergy, & Immunology
- VA Medical Center Section Chief, Allergy and Clinical Immunology
Education & Training
- FellowYale University (2012)
- Chief ResidentYale University Bridgeport Hospital (2009)
- ResidencyYale University Bridgeport Hospital (2008)
- Post Doctoral FellowshipJohns Hopkins University (2006)
- InternshipBoston Medical Center- Boston University (2004)
- MDSaint Louis University School of Medicine (2003)
- BASaint Louis University, Economics, Biology (1999)
Additional Information
Honors & Recognitions
- Advanced Emerging Leaders Program: Yale Medicine (2018)
- Emerging Leaders Program: Yale Medicine (2017)
- Elected Early Career Member of the Immunology Community of Practice (COP) Leadership Committee: FOCIS (Federation of Clinical Immunology Societies) (2013)
- Advanced Course in Basic and Clinical Immunology Travel Award: FOCIS (Federation of Clinical Immunology Societies) (2012)
- All-USA Academic Second Team: USA Today (1995)
- Presidential Scholar: Saint Louis University (1995), (1996), (1997), (1998)
- Medical Scholar: Saint Louis University (1995)
Professional Service
- Plasma Protein Therapeutics Association (PPTA) (2021 - Present): featured speaker in a Roundtable on Ig use in the United states
- Chest (2020 - Present): Reviewer
- Ad hoc COVID-19 Treatment group (2020 - Present): Reviewed literature and advised on treatment protocols during the COVID-19 pandemic
- Geriatric Chief Search Committee (2019 - 2021): Committee Member
- Yale New Haven Hospital (2019 - Present): Physician Steward for IVIG usage at Yale New Haven Hospital
- Yale (2018 - 2019): Allergy Immunology faculty recruitment search committee
- Yale Medicine (2018): Patient Access Advisory Committee: Change Management and Communication Yale Medicine
- Yale Internal Medicine (2018 - Present): representing Allergy and Immunology in Internal Medicine Clinical Leadership Meetings
- Oncology (2018 - Present): Reviewer
- Grifols (2015 - Present): Advisory Board member to Grifols regarding IgG replacement therapy use, major obstacles in the field, research initiatives and future directions
Publications
- Wang SY, Juthani PV, Borges KA, Shallow MK, Gupta A, Price C, Won CH, Chun HJ. Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era. The Lancet. Microbe 2022, 3: e4-e5. PMID: 34901896, PMCID: PMC8641954, DOI: 10.1016/S2666-5247(21)00306-2.
- Krantz MS, Kwah JH, Stone CA, Phillips EJ, Ortega G, Banerji A, Blumenthal KG. Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. JAMA Internal Medicine 2021, 181: 1530-1533. PMID: 34309623, PMCID: PMC8314170, DOI: 10.1001/jamainternmed.2021.3779.
- WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group., Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty JS, Berry LR, Broman N, Cavalcanti AB, Colman R, De Buyser SL, Derde LPG, Domingo P, Omar SF, Fernandez-Cruz A, Feuth T, Garcia F, Garcia-Vicuna R, Gonzalez-Alvaro I, Gordon AC, Haynes R, Hermine O, Horby PW, Horick NK, Kumar K, Lambrecht BN, Landray MJ, Leal L, Lederer DJ, Lorenzi E, Mariette X, Merchante N, Misnan NA, Mohan SV, Nivens MC, Oksi J, Perez-Molina JA, Pizov R, Porcher R, Postma S, Rajasuriar R, Ramanan AV, Ravaud P, Reid PD, Rutgers A, Sancho-Lopez A, Seto TB, Sivapalasingam S, Soin AS, Staplin N, Stone JH, Strohbehn GW, Sunden-Cullberg J, Torre-Cisneros J, Tsai LW, van Hoogstraten H, van Meerten T, Veiga VC, Westerweel PE, Murthy S, Diaz JV, Marshall JC, Sterne JAC. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. JAMA 2021.
- Azmy V, Kaman K, Tang D, Zhao H, Dela Cruz C, Topal JE, Malinis M, Price CC. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19. Journal Of Clinical Immunology 2021, 41: 738-747. PMID: 33459964, PMCID: PMC7812117, DOI: 10.1007/s10875-020-00949-6.
- Kaman K, Azmy V, Chichra A, Britto-Leon C, Price C. Cytokine profiles in severe SARS-CoV-2 infection requiring extracorporeal membrane oxygenation support. Respiratory Medicine Case Reports 2021, 33: 101376. PMID: 33680800, PMCID: PMC7925237, DOI: 10.1016/j.rmcr.2021.101376.
- Zhou Z, Price CC. Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease. Expert Opinion On Investigational Drugs 2020, 29: 1407-1412. PMID: 33094669, DOI: 10.1080/13543784.2020.1840549.
- Sheehan K, Price C, Hafez N. Optimizing Care for Patients With Adverse Events From Immunotherapeutics. Cancer Journal (Sudbury, Mass.) 2020, 26: 537-542. PMID: 33298725, DOI: 10.1097/PPO.0000000000000492.
- Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes. Chest 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.
- Subtle But Clinically Significant: A Review of Antibody Deficiency in AdultsHarada K, Price C. Subtle But Clinically Significant: A Review of Antibody Deficiency in Adults, Clin Pulm Med. 26(3):71-75 May 2019
- Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, Hoshino A, Kobayashi M, Imai K, Takagi M, Dybedal I, Haddock JA, Sansom DM, Lucena JM, Seidl M, Schmitt-Graeff A, Reiser V, Emmerich F, Frede N, Bulashevska A, Salzer U, Schubert D, Hayakawa S, Okada S, Kanariou M, Kucuk ZY, Chapdelaine H, Petruzelkova L, Sumnik Z, Sediva A, Slatter M, Arkwright PD, Cant A, Lorenz HM, Giese T, Lougaris V, Plebani A, Price C, Sullivan KE, Moutschen M, Litzman J, Freiberger T, van de Veerdonk FL, Recher M, Albert MH, Hauck F, Seneviratne S, Pachlopnik Schmid J, Kolios A, Unglik G, Klemann C, Speckmann C, Ehl S, Leichtner A, Blumberg R, Franke A, Snapper S, Zeissig S, Cunningham-Rundles C, Giulino-Roth L, Elemento O, Dückers G, Niehues T, Fronkova E, Kanderová V, Platt CD, Chou J, Chatila TA, Geha R, McDermott E, Bunn S, Kurzai M, Schulz A, Alsina L, Casals F, Deyà-Martinez A, Hambleton S, Kanegane H, Taskén K, Neth O, Grimbacher B. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. The Journal Of Allergy And Clinical Immunology 2018, 142: 1932-1946. PMID: 29729943, PMCID: PMC6215742, DOI: 10.1016/j.jaci.2018.02.055.
- Barmettler S, Price C. Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab--for how long? The Journal Of Allergy And Clinical Immunology 2015, 136: 1407-9. PMID: 26277594, DOI: 10.1016/j.jaci.2015.06.035.
Departments and Programs
- Allergy & Clinical Immunology
- Internal Medicine
Locations
Yale Interventional Immunology Center
6 Devine Street
Fl 2nd Ste Suite 2B
North Haven, CT 06473
- Yale Interventional Immunology Center6 Devine StreetFl 2nd Ste Suite 2BNorth Haven, CT 06473
Yale Interventional Immunology Center
6 Devine Street
Fl 2nd Ste Suite 2B
North Haven, CT 06473
- Yale Interventional Immunology Center6 Devine StreetFl 2nd Ste Suite 2BNorth Haven, CT 06473